Our brave Jasper is slowly losing the ability to walk – a drug could change that but the NHS cruelly won't fund it
LIVING NIGHTMARE Our brave Jasper is slowly losing the ability to walk – a drug could change that but the NHS cruelly won't fund it
Click to share on X/Twitter (Opens in new window)
Click to share on Facebook (Opens in new window)
THE family of a 10-year-old boy who's losing the ability to walk have described the 'nightmare' battle they face with the NHS to access a free drug for help.
Rosie and Pete Day from Horsham, West Sussex have been fighting for the drug givinostat for their son Jasper who has Duchenne muscular dystrophy (DMD).
Sign up for Scottish Sun
newsletter
Sign up
4
Jasper and his twin sister both have Duchenne muscular dystrophy - but Arabella is a carrier while Jasper is most affected
Credit: PA
4
The Day family are fighting for Jasper to get givinostat, which can slow progression of the condition
Credit: PA
Duchenne is a genetic muscle wasting condition that causes progressive muscle weakness.
In the UK, an estimated 2,500 people are living with the condition
The Day family have twins Jasper and Arabella, and two older daughters.
Both Jasper and his twin sister Arabella have Duchenne, with Arabella a carrier and Jasper the most affected - as the condition mostly affects boys.
Read more on muscle conditions
BEHIND BARS Woman left battling fatal 'muscle death' triggered by first ever spin class
Givinostat, developed by ITF Pharma UK, can slow progress of Duchenne - keeping children on their feet for longer - and is being offered for free by a drug firm while it goes through the process of NHS approval.
Only some NHS trusts across the UK, and few in England, are giving out the drug despite it being part of an early access programme since November.
Families are now facing a "cruel" postcode lottery over who gets the medicine and are in a race against time, according to the charity Duchenne UK.
Some NHS trusts are refusing to supply the drug while others delay it by drawing up lists of who they think should get it first.
NHS trusts say they need to pay for monitoring the drug - around £1,900 per year per patient - out of their own budget.
Rosie said: "We try and live in the moment and, in this moment, there's an opportunity to make a massive change to Jasper.
Toddler, 3, left fighting for life after 'going off his food' - as killer cocktail of common viruses attacked his heart
"We're not going to cure it, but this drug gives him the best chance of having the early life that he wants to have and what every parent wants to give their child.
"It's so close - and yet we're stuck.
"We're stuck in this process where there's something in reaching distance that could make a huge difference to keep him walking, keep him active, keep him with his siblings in the garden, keep him walking up the stairs, all of those things, and it just feels that we can't quite get there.
"We're on the finishing line to get something that will make a difference and we can't quite get there because of the system we're in.
"The drug is not going to cure it, but it will give him the childhood you would wish to give your child - to keep them playing football, coming on dog walks, being able to walk up the stairs, playing the French horn, all of those things that you dream your child is going to get to do.'
She added: "It feels like a nightmare, because you know that the doctors want to give it, but when it comes to getting the drug in his mouth and seeing what it would do, we're stuck.
"It's a lottery, basically, depending on where you are in the country ... and within NHS trusts themselves."
'When will I get the drug, mummy?'
Jasper is under the care of the Evelina London Children's Hospital, which is only now starting to contact patients and is drawing up a priority list for who gets the drug first.
"Every day that passes by is a day that we can see Jasper decline and see him struggling with his muscles," Mrs Day said.
"Two weeks ago, he asked me, 'When will I get the drug, mummy?'
"We're stuck in a situation over who's going to make those decisions regarding who gets the drug - of whether Jasper gets it or another boy.
"For every boy it's heartbreaking, because someone ultimately is not going to get the drug at that moment based on the current criteria."
She continued: "If Jasper stops walking, we're not going to get that back.
We're stuck in a situation over who's going to make those decisions regarding who gets the drug - of whether Jasper gets it or another boy
Rosie Day
"Every day matters. Six months ago, Jasper could walk up and down the stairs easily. He can't do that now and Pete has to push him up the stairs every night.
"Yet we can't give him something that is as simple as two spoons full of medicine and a blood test, and a little bit of maybe resource looking at the blood test results - that is what is standing in our way."
Rosie said it was unclear how the Evelina is "going to make a fair choice" because knowing who will lose mobility is not an exact science.
And she said the process is "hugely subjective" because there is no linear decline in the condition and the decisions made by NHS trusts could end up being "completely wrong".
According to Duchene UK, boys whose condition is getting worse risk falling off the list entirely while waiting for the drug.
Around 500 boys in the UK are eligible for givinostat, which can be taken at home like Calpol, with hospitals then doing follow-up blood tests of around eight in the first year, followed by twice a year thereafter.
4
Jasper is under the care of the Evelina London Children's Hospital, but it's unclear whether they'll give him the drug
Credit: PA
4
The family say the NHS needs to urgently make the drug available to both ambulant (walking) and non-ambulant boys
Credit: PA
Children may also need an ECG, though these are already part of routine Duchenne monitoring.
Emily Reuben and Alex Johnson, founders of Duchenne UK, said: "As time ticks by, more boys are losing out on their chance to access givinostat.
"This is a simple treatment, which can be easily managed at home, and requires uncomplicated blood tests to monitor. It's free to the NHS and could offer real hope for patients and their families.
"The delays are cruel and the postcode lottery is unjustifiable. We are calling on the NHS to urgently make this available to both ambulant (walking) and non-ambulant boys."
To date, all health boards in Scotland are rolling out the drug, alongside those in Swansea and Cardiff.
Leicester Royal Infirmary was the first trust in England to give the drug, but the Evelina has not yet, and neither have trusts in Manchester, Liverpool and Newcastle.
Great Ormond Street Hospital is working to supply the drug.
A spokesman for the Evelina said: "We have begun contacting families of all existing Evelina London patients who may be eligible for givinostat and are working to set up appointments in the next few months.
"Our clinical team are working through our patient lists and are currently prioritising children who need the treatment most urgently, or are at a higher risk of losing movement (ambulation) soon."
An NHS spokesman said: "The first National Institute for Health and Care Excellence (Nice) committee meeting to consider this treatment is scheduled to be held in July 2025, and if manufacturer ITF Pharma can offer a cost-effective price to enable Nice to recommend its use, the NHS will be ready to work with the company to explore fast-tracking access for patients.
"NHS England has published guidance on manufacturer-led early access schemes, which require trusts to cover substantial costs and find additional clinical resources to administer new treatments, and we understand a number of trusts across the country are preparing to offer givinostat via such a scheme."
Parents have met with Health Secretary Wes Streeting to try and speed up access.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mirror
10 minutes ago
- Daily Mirror
'Our little girl died four years ago and we're still waiting to find out why'
The grieving family of Bonnie Marsh, who died after collapsing in hospital, have been left with more bad news after being told an inquest into her death has been delayed again The devastated parents of a little girl who died after collapsing in hospital say they feel 'let down again and again" as a long-awaited inquest into her death is delayed yet again, nearly four years on. Bonnie Marsh, just four years old, tragically died in December 2021 after falling seriously ill with vomiting and exhaustion. Despite three visits to hospital, where her mum says she was 'dying in her arms', the bubbly schoolgirl was not admitted until it was too late Now, her grieving parents Lauren and Liam Marsh are still fighting for answers, but the inquest they had hoped would finally give them closure has been pushed back once more. And the heartbroken couple have revealed a string of horrifying discoveries in the wake of their daughter's death — including learning her body had been frozen without their consent. Mum Lauren, 33, said: "She's my daughter, but it feels like she's been the NHS 's property since she died. We were finally at the point of getting answers, and it's been taken away from us. We've just been let down again.' Bonnie, who had just started school and adored Disney's The Lion King, seemed full of a cold on December 14 four years ago when she came home from school. Two days later, she passed out in the bathroom after being sick. Paramedics told her family her observations were 'fine' and said the hospital wasn't necessary. But her concerned mum insisted on taking her in anyway, explaining: "She was still being sick, floppy and lethargic." Bonnie was seen again at Norfolk and Norwich Hospital the following day but sent home. On December 18, Lauren knew something was seriously wrong. She added: "She was freezing cold, floppy and dying in my arms. I was wandering around the hospital begging someone to help.' A cleaner, not a nurse or doctor, eventually guided her to the Children's Assessment Unit and said the tot was "very poorly," Lauren explained. As Bonnie's condition worsened, doctors handed Lauren a syringe and told her to feed her daughter tiny drops of water, despite her being close to death. Lauren said: 'They gave me the syringe to put water in my dying daughter's mouth. They said they'd restarted her heart and were transferring her by helicopter. But before we could leave, doctors ran back into the room. They said it was time to say goodbye — but when I walked in, she was already gone.' Ever since the tragic death, Lauren says her family haven't received any support or guidance and that police weren't contacted about the sudden death. Initially, the cause of death was said to be dehydration due to norovirus. A post-mortem later showed Bonnie had also tested positive for Covid and flu. But then doctors at N&N said she may have died due to a genetic condition, and an interim death certificate listed an 'inborn error of metabolism'. However, specialists at Addenbrooke's, Great Ormond Street, and even a clinic in Germany all found no evidence of any such condition. To make matters worse, the family were told after her death that Bonnie's body had been frozen to preserve samples. Lauren added: 'I hadn't signed anything. I had no idea. I was heartbroken. When I finally saw her, she didn't look like my Bonnie anymore.' Bonnie's inquest was finally scheduled to begin this July, but just three days before it was due to start, the family were told it was being postponed again because a witness was unavailable. At a brief hearing, area coroner Johanna Thompson said: "Bonnie's inquest was due to take place this week, but there were difficulties with the attending witness… It has now been relisted for October 29 and 30.' However, the family aren't hopeful anything will get done this time and are refusing to put it in their calendar. Lauren explained: "Every delay sets us back three months. Every time, someone needs more time to review evidence. I don't think we're going to get an apology. I just want a concrete answer about what my daughter died from.' In a statement, Tracey Bleakley, Executive Managing Director at Norfolk and Norwich University Hospital, said: "Our deepest condolences are with Bonnie's family following their loss and we are sorry to hear there have been delays in the inquest process. It is entirely right that the circumstances are fully reviewed by the coroner following our own internal review. A full inquest… will provide the opportunity to answer all the family's questions.'
BBC News
10 minutes ago
- BBC News
Bridgwater £17.8m diagnostic centre to improve access to 'vital scans'
A hospital trust has moved a step forward in its plans to construct a £17.8m diagnostic centre to improve access to vital NHS Foundation Trust has been given approval by NHS England to construct the facility next to Bridgwater Community Hospital. It said it has now applied for planning permission, which if approved could see the facility open next centre will run a range of services including two CT scanners, two MRI scanners, four outpatient rooms and two echocardiography and ultrasound director David Craig said the centre is "expected to provide almost 25,000 additional scans every year". This will enable the centre to provide the Bridgwater population with routine and specialist cardiac and cancer scanning, alongside clinics. It follows the opening of a community diagnostic centre in Taunton in 2020, as well as the development of a diagnostic centre next to Yeovil Hospital, which is expected to open later this year."This development is fantastic news for people in Bridgwater and will improve access to vital healthcare scans, as well as help us to reduce our waiting times," Mr Craig said."The new centre supports one of the three shifts of the NHS 10 Year Plan, which involves transferring care from hospitals into local communities."Running across seven days a week, it will improve access for people in Bridgwater and the surrounding areas to specialist care, with the centre expected to provide almost 25,000 additional scans every year."
Telegraph
40 minutes ago
- Telegraph
We'll use AI to spot more prostate cancer, says Science Secretary
Artificial Intelligence will be harnessed to find hidden cases of prostate cancer, the Science Secretary has said. Peter Kyle told The Telegraph that the Government is investing £168m on initiatives to use public data better and one major goal is to improve cancer screening on the NHS. A world-leading initiative led by Cancer Research UK has been given £10m in funding to improve cancer screening methods by identifying the most at-risk people and offering them personalised tests. The funding will 'develop AI-powered tools that can predict cancer risk', Mr Kyle said, and could save thousands of lives a year. The Telegraph has launched a campaign calling for a targeted national screening programme for prostate cancer, which focusses on men who are at the greatest risk. This includes men over 50, black men, whose risk is twice that of white men, and those with a family history of prostate cancer. Steve McQueen, Bob Willis and Chris Hoy are some of the high-profile British men to be recently diagnosed with the condition. Around 55,000 men are diagnosed with prostate cancer annually in England and around 33 men a day die from the condition. Writing for The Telegraph alongside Stian Westlake, the executive chairman of the Economic and Social Research Council, Mr Kyle said: 'This funding will support work on a project linking health records to demographics, family history and behaviour to identify those at higher risk of this devastating illness, so that it can be treated early – potentially saving thousands of lives every year.' The plan is to create flexible national screening programmes which can pick up more cases in individuals who may otherwise be missed and diagnosed only when the cancer was incurable. Officials are hoping to replicate the success of BRCA1 genetic screening. Around one in 400 people has faulty BRCA genes, which give women a 60 per cent chance of developing breast cancer. This received widespread attention and became known as the 'Angelina Jolie gene' after the Hollywood actress underwent a double mastectomy after finding out she was a carrier in 2013. The NHS now offers genetic tests to high-risk groups, such as Jewish women, to catch as many cases early as possible. Mr Kyle said: 'Just as BRCA gene screening, heroically brought to the fore by campaigners including Angelina Jolie, revolutionised how we understand and manage the risk of hereditary breast cancer, this next generation of data-driven screening could do the same for more cancers, including prostate cancer.' Scientists running the scheme hope it can enable the NHS to offer more frequent cancer screening sessions or screening at a younger age to those at higher risk, while those at lower risk could be spared unnecessary tests. People identified as higher risk could also be sent for cancer testing faster when they go to their GP with possible symptoms. The wider Administrative Data Partnership will last until 2031 and try to repurpose data that already exists to make improvements to the judicial service, education, health and other public sectors. Combining, standardising and interpreting different datasets simultaneously is a daunting challenge for scientists owing to decades of independent data collection and little crossover. However, the Government believes that vast data reserves, combined with the power of AI computing, could transform healthcare. The cancer screening project will build new models over the next five years to merge relevant data as well as creating algorithms which will process it and ensure the results are accurate and reliable. Antonis Antoniou, the programme director and professor of cancer risk prediction at the University of Cambridge, said: 'The UK's strengths in population-scale data resources, combined with advanced analytical tools like AI, offer tremendous opportunities to link disparate datasets and uncover clues that could lead to earlier detection, diagnosis, and prevention of more cancers.' Dr David Crosby, the head of prevention and early detection research at Cancer Research UK, told The Telegraph: 'The single most important thing we can do to beat cancer is to find it earlier, when treatment is more likely to be successful. 'With half a million cancer cases per year expected in the UK by 2040, we need a major shift towards more accurate diagnosis and detection of early cancer. 'The Cancer Data Driven Detection programme will link health data sources together and build the powerful new tools doctors need to identify those at highest risk of cancer and prioritise resources towards them. 'Moving towards a preventative approach to healthcare will not be easy and will take time. Cancer Research UK's investment in the programme is an investment in the future of cancer care.' Data is the key to changing lives for the better By Peter Kyle and Stian Westlake For much of our everyday lives, data is king – from digital maps getting us from A to B, to health apps keeping our fitness and sleep in check, to even streaming platforms suggesting the next drama we might want to get stuck into. For this government, making good use of data is the difference between successful policies that are rooted in evidence, and those that rely on hope, luck or intuition, which no minister, legislator or council leader wants to rely on. Ultimately data is the bedrock of decision-making, ensuring policies, programmes and funding are doing what they are intended to do – changing lives for the better. Linking data from across government to the national pupil database for example can help to really dig into the source of inequalities that trap too many Brits from childhood through to the labour market – helping us to take targeted action in boosting social mobility and shattering glass ceilings. Or by better applying it in the justice system, we can understand patterns of reoffending, stopping career criminals from inflicting more misery on the law-abiding majority. And it can forecast the impact that this government extending the national living wage has on younger workers, so that millions more who put the hours in take home the pay they deserve. What unites all of these examples is that they were all made possible by UKRI's administrative data research UK partnership. It works to connect, and make sense of, the huge wealth of data that is generated by government services, bringing it to our world class researchers securely and with the public's privacy at heart since 2018. In short it has been demonstrating the role data can play in improving lives in as many ways as we can imagine and more. But we know we can go further and too many social and economic researchers – many of the very best of whom are right here in the UK – simply can't access the data they need. It is fragmented and siloed, held in different datasets by different public organisations. That means too many rely instead on insights from abroad, which while offering much, simply can't tell the full story of life in Britain in 2025. Accessing the raw resource of all that data and translating it into a form that researchers can use is no easy task, and while we need to grow our data science expertise, we also need to build relationships and make the case to other organisations that secure data sharing has the power to change lives. That is why UKRI is investing a further £168m to continue ADR UK's programme of work through to 2031. This includes continuing our partnership with Cancer Research UK to develop AI-powered tools that can predict cancer risk based on health records, family history and behaviour. Just as BRCA gene screening, heroically brought to the fore by campaigners including Angelina Jolie, revolutionised how we understand and manage the risk of hereditary breast cancer, this next generation of data-driven screening could do the same for more cancers, including prostate cancer. This funding will support work with organisations and charities like Cancer Research UK for example, on a project linking health records to demographics, family history, and behaviour to identify those at higher risk of this devastating illness, so that it can be treated early – potentially saving thousands of lives every year. The ADR will also offer learnings for and help us shape our new national data library, a central government resource designed to bring together existing research programmes and make it easier for policymakers and public bodies to access and use data securely to improve public services. As the incredible opportunities and challenges of technology like AI advance at unprecedented speeds and as we grapple with the fate of our planet as our climate changes, using data to drive policy for the generations to come has never been more important. This government is driven by a plan for change that will transform the lives of the British people, from growing our economy so that our payslips go further, to unlocking opportunity for everyone regardless of background, and building an NHS that is fit for the future and makes the most of the opportunities in new technology. Data can play a huge part in getting that right and targeting government support where it is needed most.
